SPOTLIGHT -
EP. 1: Differential Diagnosis and Staging of Follicular Lymphoma
EP. 2: The Importance of Risk Assessment
EP. 3: When to Initiate Therapy for Follicular Lymphoma
EP. 4: Immunochemotherapy Decision Factors
EP. 5: Phase III GALLIUM Results and Maintenance Therapy
EP. 6: Determining Second-Line Therapy in FL
EP. 7: Relapsed/Refractory Treatment: The MAGNIFY Regimen
EP. 8: Treatment Options After Second-Line Relapse
EP. 9: The DYNAMO Later-Line Regimen
EP. 10: Sequencing Strategies for Later-Line Therapy
EP. 11: The Phase II EZH2 Inhibitor Trial
EP. 12: Previously Untreated FL: Obinutuzumab Plus Lenalidomide
EP. 13: The Phase III GADOLIN Trial
EP. 14: Phase Ib Polatuzumab Vedotin Trial
EP. 15: The Future Landscape of Follicular Lymphoma Treatment
Long-Term HRQOL Remains Unimpaired With HIPEC Plus Cytoreductive Surgery in Newly Diagnosed Ovarian Cancer
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC